Galleon Pharmaceuticals, Inc. Reports Positive Results from Phase I Study of GAL-021 For Treatment of Respiratory Depression

Published: May 07, 2012

HORSHAM, Pa.--(BUSINESS WIRE)--Galleon Pharmaceuticals, a leader in the development of novel medicines to treat breathing disorders, today announced that its investigational drug GAL-021 appeared to be safe and well-tolerated and demonstrated dose-proportional pharmacokinetic effects on respiration in a Phase I clinical study of 30 healthy adults. GAL-021 increased minute ventilation, the capacity measure of air supplied to the lungs, by 27 percent compared to placebo. Based upon these findings, Galleon plans to evaluate the effects of GAL-021 on breathing in subjects administered opioids, which are well-known respiratory depressants.

Back to news